Positron emission tomography in oncology: General acceptance of its role is overdue
- 15 November 1996
- Vol. 78 (10) , 2039-2042
- https://doi.org/10.1002/(sici)1097-0142(19961115)78:10<2039::aid-cncr1>3.0.co;2-j
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolizationCancer, 1996
- Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.Radiology, 1996
- Occult primary tumors of the head and neck: detection with 2-[F-18] fluoro-2-deoxy-D-glucose SPECT.Radiology, 1996
- Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose.Radiology, 1996
- Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liverThe American Journal of Surgery, 1996
- Proceedings of a National Cancer Institute workshop: PET in oncology--a clinical research agenda.Radiology, 1994
- Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancerBritish Journal of Surgery, 1994
- Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation.Radiology, 1994
- Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging.RadioGraphics, 1993
- Positron Emission Tomography (PET) in Neuroendocrine Gastrointestinal TumorsActa Oncologica, 1993